Accretion Pharmaceuticals Ltd (ACCPL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Accretion Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Accretion Pharmaceuticals Limited has informed the Exchange about Investor Presentation
Investor Presentation · 03 Nov 2026, 10:55 pm
Accretion Pharmaceuticals Delivers Robust H1 FY27 Growth with PAT Surging 72.63% YoY Accretion Pharmaceuticals reported a strong performance for H1 FY27, with revenue from operations growing 25.83% YoY to ₹55.04 crore. EBITDA jumped 72.28% YoY to ₹12.37 crore as EBITDA margin expanded 606 bps to 22.48%. Net profit surged 72.63% YoY to ₹8.20 crore, expanding PAT margins by 403 bps to 14.90%. Export contribution doubled to 18.15% from 9.16% in H1 FY26. Growth was driven by an improved product mix, capacity additions, and expanding international presence across 30+ countries, alongside ongoing CAPEX for facility expansion.
Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 02 Nov 2026, 5:38 pm
Accretion Pharmaceuticals Reports Strong H1 FY27 Performance with 72.6% PAT Surge Accretion Pharmaceuticals reported revenue from operations of ₹5,504.10 lakhs for the half-year ended 30th Sep'26, up 25.8% YoY from ₹4,373.62 lakhs. Profit Before Tax climbed 69.2% YoY to ₹1,084.49 lakhs compared to ₹641.07 lakhs in H1 FY26. Net profit surged 72.6% YoY to ₹820.14 lakhs from ₹475.22 lakhs, expanding diluted EPS to ₹7.38 from ₹4.61. Operating cash outflow stood at ₹312.14 lakhs due to working capital additions. Net worth reached ₹6,291.00 lakhs with total borrowings at ₹1,673.70 lakhs.
Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2026, titled "Company Reports 25.83% Revenue Growth and 72.63% PAT Growth in H1 FY27 and Strong EBITDA Growth of 72.28%; EBITDA Margin Improves to 22.48%".
Press Release · 31 Oct 2026, 10:53 pm
Accretion Pharmaceuticals Posts Robust H1 FY27 Performance with PAT Surging 72.63% YoY Accretion Pharmaceuticals reported a 25.83% YoY increase in net revenue to ₹55.04 crore for H1 FY27 ending 30th Sep'26, driven by volume growth and an improved product mix. EBITDA grew 72.28% YoY to ₹12.37 crore, with EBITDA margin expanding 606 bps to 22.48%. PAT jumped 72.63% YoY to ₹8.20 crore, expanding PAT margin by 403 bps to 14.90%. Basic EPS rose to ₹7.38 from ₹4.61 in H1 FY26. Export revenue contribution nearly doubled to 18.15% from 9.16% YoY.
Accretion Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the half year ended September 30, 2026.
Outcome · 31 Oct 2026, 6:24 pm
Accretion Pharmaceuticals Reports Strong H1 FY27 Growth with PAT Rising 72.6% YoY Accretion Pharmaceuticals reported a 25.8% YoY increase in revenue from operations to ₹5,504.10 lakhs for the half-year ended 30th Sep'26, compared to ₹4,373.62 lakhs in H1 FY26. Net profit surged 72.6% YoY to ₹820.14 lakhs from ₹475.22 lakhs, expanding basic EPS to ₹7.38 from ₹4.61. Profit before tax rose 69.2% YoY to ₹1,084.49 lakhs. Working capital build drove negative operating cash flow of ₹312.14 lakhs. Total net worth stood at ₹6,291.00 lakhs with closing cash equivalents of ₹212.67 lakhs as of 30th Sep'26.
Accretion Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 31-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 31 Oct 2026, 5:30 am
Accretion Pharmaceuticals Schedules Board Meeting to Consider Half-Year Results Accretion Pharmaceuticals Limited has notified the stock exchanges that a meeting of its Board of Directors is scheduled for 31st Oct'26. The board will inter-alia consider and approve the company's unaudited financial results for the half-year ended Sep'26.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 31 Oct 2026, 5:30 am
Accretion Pharmaceuticals Schedules Board Meeting for Half-Year Financial Results Accretion Pharmaceuticals Limited has scheduled a meeting of its Board of Directors for 31st Oct'26. The board will convene inter-alia to consider and approve the company's Unaudited Financial Results for the half-year ended 30th Sep'26.
Accretion Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report.
Annual General Meeting · 12 Oct 2026, 6:44 pm
Accretion Pharmaceuticals Shareholders Approve Key Special Resolutions via Postal Ballot Accretion Pharmaceuticals Limited announced the passing of all five special resolutions via postal ballot with 100% shareholder approval for valid votes cast during e-voting concluded on 9th Oct'26. Approved items include alterations to the Memorandum of Association, increased borrowing limits under Section 180(1)(c), creation of security/mortgages under Section 180(1)(a), revised limits for loans, guarantees, and securities to subsidiaries under Section 185, and enhanced loan, guarantee, and investment limits under Section 186 of the Companies Act, 2013. The company also submitted a revised scrutinizer's report rectifying minor typographical errors.
Accretion Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
Others (Uncategorized) · 11 Oct 2026, 12:23 am
Accretion Pharmaceuticals Alters Memorandum of Association Object Clause Following Shareholder Approval Accretion Pharmaceuticals Limited received shareholder approval via postal ballot on 9th Oct'26 to alter Clause III (Object Clause) of its Memorandum of Association. The approved amendment substitutes Main Object Clause III(A) and inserts new sub-clauses numbered III(B)(10) through III(B)(47). The expanded mandate broadly covers manufacturing, trading, research, and distribution across pharmaceuticals, nutraceuticals, medical devices, healthcare facilities, diagnostic centers, clinical research organizations, consumer food items, and global strategic investments.
Accretion Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot
Annual General Meeting · 11 Oct 2026, 12:18 am
Accretion Pharmaceuticals Shareholders Approve All Five Special Resolutions via Postal Ballot Accretion Pharmaceuticals Limited announced the approval of all five special resolutions via postal ballot concluded on 9th Oct'26, as per the scrutinizer's report dated 10th Oct'26. Key approved resolutions include altering the Memorandum of Association, increasing borrowing limits under Section 180(1)(c), creating charges on assets under Section 180(1)(a), and expanding loan, guarantee, and investment limits under Sections 185 and 186 of the Companies Act, 2013. All resolutions received 100% favorable votes from total valid votes cast, passing with the requisite majority.
Accretion Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot
Annual General Meeting · 11 Oct 2026, 12:15 am
Accretion Pharmaceuticals Shareholders Approve All Five Special Resolutions via Postal Ballot Accretion Pharmaceuticals Limited announced the approval of five special resolutions via postal ballot concluded on 9th Oct'26. Shareholders unanimously approved alterations to the Memorandum of Association, higher borrowing limits under Section 180(1)(c), creation of security/mortgages under Section 180(1)(a), and expanded limits for inter-corporate loans, guarantees, and investments under Section 186 with 100% of valid votes (8,256,400 votes). Additionally, revised limits for extending loans, guarantees, or security to subsidiaries under Section 185 passed with 100% of valid votes (84,000 votes). All resolutions were passed with the requisite majority.
Accretion Pharmaceuticals Limited has informed regarding Submission of the Compliance Report on Non-Applicability of Corporate Governance for the Q2 FY 2026-27.
Others (Uncategorized) · 10 Oct 2026, 9:17 pm
Accretion Pharmaceuticals Exempt From Q2 FY27 Corporate Governance Reporting Accretion Pharmaceuticals Limited confirmed the non-applicability of Regulation 27(2) of SEBI LODR Regulations, 2015, regarding the submission of quarterly Corporate Governance compliance reports for the quarter ended 30th Sep'26 (Q2 FY27). Under Regulation 15(2)(b), entities with securities listed on the SME Exchange (NSE Emerge Platform) are exempt from these governance provisions. The filing is supported by a certification from practicing company secretary firm M/s Sakhiya & Co., dated 9th Oct'26, confirming the regulatory exemption.
Accretion Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
Annual General Meeting · 10 Sept 2026, 2:01 am
Accretion Pharmaceuticals Seeks Shareholder Approval for Major Limit Hikes and MOA Alteration Accretion Pharmaceuticals Limited has issued a Postal Ballot notice seeking shareholder approval for key strategic and financial proposals. The company proposes altering its MOA Object Clause to support expansion into broader healthcare, diagnostic, and dietary sectors. Additionally, it plans to raise its borrowing limits from ₹100 crore to ₹500 crore over paid-up capital, free reserves, and share premium under Section 180(1)(c). Further proposals include enhancing limits for loans, guarantees, and securities to subsidiaries (Section 185) and inter-corporate investments (Section 186) up to ₹100 crore each. Remote e-voting runs from 10th Sep'26 to 9th Oct'26.
Accretion Pharmaceuticals Limited has informed the Exchange about General Updates
Others (Uncategorized) · 01 Sept 2026, 7:16 pm
Accretion Pharma Board Approves Key Financial and Structural Changes Accretion Pharmaceuticals' board, on 1st Sep'26, approved key proposals subject to shareholder consent. These include altering the MOA's object clause to expand business activities and raising borrowing limits under Section 180(1)(c). The board also approved enhancing limits for creating charges on assets under Section 180(1)(a). Additionally, proposals were passed for advancing loans/guarantees to related parties and exceeding prescribed limits for loans, guarantees, and investments. All approvals are contingent on a forthcoming postal ballot for shareholder ratification.
Accretion Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
Others (Uncategorized) · 01 Sept 2026, 7:15 pm
Accretion Pharma Board Approves Key Proposals for Shareholder Vote Accretion Pharmaceuticals' Board, on 1st Sep'26, approved key proposals subject to shareholder approval via postal ballot. These include altering the company's Object Clause in its Memorandum of Association to expand business activities. The Board also seeks to increase borrowing limits, enhance limits for creating security on company assets, and approve loans, guarantees, and investments exceeding prescribed thresholds under the Companies Act, 2013. These moves signal potential strategic expansion and future capital-raising activities, pending shareholder and regulatory consent.
Accretion Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 27, 2026
Annual General Meeting · 28 Aug 2026, 1:23 am
Accretion Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 27, 2026
Annual General Meeting · 27 Aug 2026, 9:34 pm
Accretion Pharmaceuticals Limited has informed the Exchange about General Updates - Letter regarding web Link of Annual Report to Shareholders
Annual Report · 05 Aug 2026, 10:08 pm
Accretion Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2026
Annual General Meeting · 04 Aug 2026, 1:08 am
Accretion Pharmaceuticals Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__
Others (Uncategorized) · 07 Jul 2026, 11:19 pm
Accretion Pharmaceuticals Exempted from Q1FY27 Corporate Governance Reporting Accretion Pharmaceuticals Limited (ACCPL) has notified the exchange on 7th Jul'26 that it is not required to submit the quarterly corporate governance compliance report for the quarter ended 30th Jun'26. This exemption is under Regulation 15(2)(b) of SEBI (LODR) Regulations, 2015, which applies to companies listed on the SME Emerge Platform. A certificate from its Practicing Company Secretary, M/s Sakhiya and Co, confirming this non-applicability has been submitted.
Accretion Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP
Change in Management · 06 Jul 2026, 8:28 pm
Accretion Pharmaceuticals Limited has informed the Exchange regarding Resignation of Ms Bandana Kumari as HR Manager of the company w.e.f. July 02, 2026.
Change in Management · 02 Jul 2026, 9:17 pm
Accretion Pharma HR Manager Resigns Accretion Pharmaceuticals announced the resignation of its HR Manager, Ms. Bandana Kumari, effective 2nd Jul'26. The departure is attributed to personal reasons. This change in senior management was disclosed as per SEBI's Listing Obligations and Disclosure Requirements regulations. No other material reasons for the resignation were cited.
The Exchange had sought clarification from Accretion Pharmaceuticals Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Others (Uncategorized) · 25 Jun 2026, 10:06 pm
Accretion Pharma Reports 93% Utilization of IPO Proceeds as of Sep'25 Accretion Pharmaceuticals (ACCPL) has utilized ₹2,775.46 lakh, or 93.3% of its total IPO proceeds of ₹2,975.46 lakh, as of 30th Sep'25. Key allocations include ₹1,358.76 lakh for working capital and ₹374.81 lakh for manufacturing facility upgrades. Capital expenditure on new equipment was fully utilized at ₹269.73 lakh. The remaining unutilized fund balance stands at ₹200.00 lakh. The utilization was certified by statutory auditors VSSB & Associates on 14th Nov'25 and is in line with the objects stated in the prospectus.